Companies › Delcath Systems
3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Melphalan/Hepatic Delivery System (HDS) Alkylating agent with liver-directed delivery via hepatic perfusion | – | Phase 3 | Metastatic Ocular Melanoma | – |
| Melphalan/HDS High-dose melphalan delivered directly into the liver via hepatic artery infusion | – | Phase 2 | Refractory Metastatic Colorectal Cancer | Dec 2026 |
| Melphalan/HDS High-dose melphalan delivered directly to the liver via hepatic artery infusion | MELK | Phase 2 | Metastatic Breast Cancer in the Liver | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05022901 | Melphalan/Hepatic Delivery System (HDS) | Phase 3 | Metastatic Ocular Melanoma | Oncology | Mar 2024 |
| NCT06607458 | Melphalan/HDS | Phase 2 | Refractory Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT06875128 | Melphalan/HDS | Phase 2 | Metastatic Breast Cancer in the Liver | Oncology | May 2029 |
Cash and short-term investments of $104m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
CG Oncology Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology Neuboron Bio-SciTech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.